Greg Behar

Witha profound commitment to a 'customer-first' approach, Greg’s vision for Recipharm is to be the leader in delivering high-quality solutions that drive success for its customers. Greg joined Recipharm in January 2024 from Nestle Health Science (NHSc) where he was CEO, and a member of the Nestlé Executive Board. Prior to NHSc, Greg held the position of CEO at Boehringer Ingelheim Pharmaceuticals USA and led a zone leadership for the Group. His extensive experience includes pivotal roles at Novartis in general management, sales and marketing in Spain and the European zone. Greg also worked at Novartis in general management, sales and marketing roles. Greg holds an MBA from INSEAD, a Masters in Engineering from the Institute of Technology of Switzerland (EPFL) and a BS in Mechanical Engineering from UCLA. Currently serving on the boards of Sonova AG and Amazentis SA, Greg has a notable history of board memberships, including Prometheus Bioscience (acquired in 2023 by Merck for $11Bio), Seres Therapeutics, and Axcella Health.